Vac­ci­body gets a new name and loads up with near­ly $1B in biobucks for new vac­cine pact with Re­gen­eron

Vac­ci­body who? A lit­tle over a year af­ter se­cur­ing a $700 mil­lion-plus deal with Roche for its neoanti­gen can­cer vac­cine, the Nor­we­gian biotech has at­tract­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER